Most Popular

M & A Deals | M & A League Table | Real Assets | Sector Events |  Private Capital Conference

Germany: Maguar Capital invests in Schlafender Hase’s next phase of growth

Buy Out Nick Herbert -
Maguar Capital, a German technology investor specialising in small and mid-sized B2B software companies, has entered into an agreement to acquire a majority stake in Schlafender Hase, a content verification platform built for regulated industries. “Schlafender Hase has built an outstanding market position,” said Johannes Losbichler, partner at Maguar Capital....

UK: Silence prices upsized US$175m ADS offering

Life Sciences Nick Herbert -
Silence Therapeutics, a global clinical-stage biotechnology company developing novel short interfering RNA (siRNA) therapies, has priced its previously announced underwritten public offering of 12,962,963 ADS, each representing three ordinary shares of £0.05 each, at US$13.50 per ADS. There is also a 30-day option for the underwriters to purchase up to an additional 1,944,444 ADS. Gross proceeds are expected to be approximately US$175m. Jefferies, Morgan Stanley, Cantor and William Blair are joint book-runners.